Welcome to our dedicated page for Heartbeam news (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on Heartbeam stock.
HeartBeam, Inc. develops medical technology for ambulatory cardiac monitoring, centered on a patented cable-free 3D ECG platform that captures signals from three non-coplanar dimensions and synthesizes a 12-lead ECG. News commonly covers the FDA-cleared HeartBeam System for arrhythmia assessment, limited commercial launch activity, preventive cardiology and concierge practice deployments, AI-ECG collaboration, and development of on-demand patch and heart attack detection initiatives.
Corporate updates also include financial results and common-stock financing used to support commercialization, product development, AI capabilities, working capital, and general corporate purposes.
HeartBeam (NASDAQ: BEAT) has announced its upcoming first quarter 2025 earnings conference call, scheduled for Tuesday, May 13, 2025, at 4:30 p.m. Eastern time. The call will be hosted by CEO Robert Eno and CFO Timothy Cruickshank, who will discuss Q1 2025 results, regulatory initiatives, commercial-readiness activities, and anticipated milestones. A detailed press release will be issued before the call.
The conference call will include a presentation accessible during the webcast and afterward through the company's investor relations website. A replay will be available for three months until August 13, 2025, through both domestic (1-844-512-2921) and international (1-412-317-6671) dial-in numbers.
HeartBeam has achieved a significant breakthrough in cardiac care technology, announcing successful clinical endpoints in its VALID-ECG pivotal study for its synthesized 12-lead ECG technology. The study, presented at the Heart Rhythm Society's conference in San Diego, demonstrated a 93.4% overall diagnostic agreement with standard 12-lead ECGs for arrhythmia assessment.
The company's innovative solution uses a credit card-sized device featuring patented 3D ECG technology that captures heart electrical signals in 3 non-coplanar directions. These signals are then transformed into a 12-lead ECG using a personalized matrix.
Key highlights:
- FDA application submitted in January 2025 for the 12-lead ECG synthesis software
- Early Access Program launched to gather clinical workflow feedback
- Multicenter trial conducted across 5 major US clinical sites with 198 patients
- Participating institutions include Allegheny Health Network, Mount Sinai Hospital, and Piedmont Heart Institute
The company plans to begin commercialization upon receiving FDA clearance.
HeartBeam (NASDAQ: BEAT) has announced a strategic collaboration with AccurKardia to advance cardiac monitoring innovation. The partnership will integrate AccurKardia's FDA-cleared ECG analysis software, AccurECG™, into HeartBeam's devices.
HeartBeam's innovative technology features a credit card-sized, cable-free 3D ECG device that captures heart signals in 3 non-coplanar directions and converts them into a 12-lead ECG using a personalized transformation matrix. The company plans to begin commercialization after receiving FDA clearance for the 12-lead ECG synthesis software.
The collaboration aims to enhance cardiac monitoring accessibility by combining HeartBeam's device with AccurKardia's automated ECG interpretation platform, enabling faster diagnosis and improved access to clinical care. This partnership is expected to accelerate HeartBeam's product development while reducing costs and timelines.
HeartBeam (NASDAQ: BEAT) reported its Q4 and full year 2024 results, marking significant milestones in cardiac care technology. The company received FDA 510(k) clearance for its HeartBeam System for arrhythmia assessment and launched an Early Access Program. They also submitted a 510(k) application for their 12-lead ECG synthesis software.
Financial highlights include securing $11.5 million in gross proceeds from a public offering. Q4 2024 showed R&D expenses of $2.9M (vs $2.0M in Q4 2023) and G&A expenses of $2.1M. The company reported a net loss of $4.9M for Q4 2024 and $19.4M for the full year. Cash position stood at $2.4M as of December 31, 2024.
Clinical progress includes presenting positive results at the American Heart Association conference, demonstrating comparable performance between HeartBeam's synthesized 12-lead ECG and standard ECGs for arrhythmia detection.
HeartBeam (NASDAQ: BEAT), a cardiac care medical technology company, has announced its participation in two major conferences in Dana Point, California during March 2025. CEO Robert Eno and CFO Timothy Cruickshank will attend:
- The 37th Annual Roth Conference at The Laguna Cliffs Marriott Resort & Spa from March 16-18, 2025
- The LSI USA '25 Conference at the Waldorf Astoria, Monarch Beach from March 17-21, 2025
Investors interested in one-on-one meetings with HeartBeam management can arrange appointments through their conference representatives or by contacting BEAT@mzgroup.us.
HeartBeam (NASDAQ: BEAT), a medical technology company specializing in cardiac care through personalized insights, has scheduled its Q4 and Full Year 2024 earnings conference call for March 13, 2025, at 4:30 p.m. Eastern time.
The call will feature CEO Robert Eno and CFO Timothy Cruickshank, who will discuss financial results, provide updates on regulatory initiatives, commercial-readiness activities, and anticipated milestones. A detailed press release will be issued before the call, and a presentation will be available during the webcast and afterward through the company's investor relations website.
HeartBeam (NASDAQ: BEAT) has successfully completed the over-allotment option of its public offering, with the underwriter purchasing an additional 864,033 shares at $1.70 per share, generating approximately $1.5 million in additional gross proceeds. This follows the firm commitment underwritten offering of 5,882,353 shares that closed on February 14, 2025.
The total offering now comprises 6,746,386 shares with gross proceeds of approximately $11.5 million. MDB Capital acted as the underwriter, with Paulson Investment Company participating as a selected dealer. The over-allotment option closed on February 25, 2025.
The company plans to utilize the net proceeds for:
- Commercial-readiness activities
- Investments in R&D, clinical, and regulatory projects
- Working capital
- General corporate purposes
HeartBeam (NASDAQ: BEAT) has announced pricing for its underwritten public offering of 5,882,353 shares of common stock at $1.70 per share, expecting to raise $10.0 million in gross proceeds. The offering is anticipated to close around February 14, 2025.
The company has granted underwriters a 45-day option to purchase up to 882,353 additional shares to cover over-allotments. MDB Capital is serving as the underwriter, with Paulson Investment Company participating as a selected dealer.
The proceeds will support HeartBeam's strategic initiatives, including commercial-readiness activities, R&D investments, clinical and regulatory projects, working capital, and general corporate purposes. This funding follows the recent FDA clearance of HeartBeam's system for comprehensive arrhythmia assessment.
HeartBeam (NASDAQ: BEAT) has submitted a 510(k) application to the FDA for its 12-lead ECG synthesis software, designed for assessing various cardiac rhythms and arrhythmias. The submission is supported by the VALID-ECG pivotal study, which enrolled 198 patients across five clinical sites.
The software builds on HeartBeam's recently FDA-cleared technology that captures heart electrical signals from three directions and synthesizes them into a 12-lead ECG using a personalized transformation matrix. The company plans to launch commercially upon FDA clearance, with hundreds of physicians and patients already on the waitlist.
Data from an 80-person pilot study presented at the AHA Scientific Sessions showed excellent agreement between HeartBeam's synthesized ECGs and standard 12-lead ECGs for arrhythmia detection, with 94% sensitivity and 100% specificity. The company plans to present VALID-ECG results at a scientific conference in 2025.
HeartBeam (NASDAQ: BEAT) announced its participation in the JP Morgan 2025 Annual Healthcare Conference, scheduled for January 13-16, 2025, in San Francisco. The company's leadership will be available for meetings to discuss their recently FDA-cleared HeartBeam system for comprehensive arrhythmia assessment.
The breakthrough device, the first of its kind to receive FDA clearance, features a credit card-sized form factor and cable-free design. It uniquely captures ECG signals from three distinct directions, providing actionable heart health information. The company plans to implement an Early Access Program and aims to leverage AI technology to analyze longitudinal ECG data, potentially predicting cardiac conditions before symptom onset.